CIBC initiated coverage on shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) in a note issued to investors on Thursday. The firm set a “market perform” rating on the stock.

Several other equities research analysts have also commented on the company. Oppenheimer Holdings, Inc. began coverage on Pacira Pharmaceuticals in a research report on Thursday. They set a “market perform” rating on the stock. UBS AG began coverage on Pacira Pharmaceuticals in a research report on Wednesday. They set a “market perform” rating on the stock. Royal Bank Of Canada restated an “outperform” rating and set a $54.00 target price on shares of Pacira Pharmaceuticals in a research report on Tuesday. Canaccord Genuity cut their target price on Pacira Pharmaceuticals from $56.00 to $48.00 and set a “buy” rating on the stock in a research report on Tuesday, August 29th. Finally, Wedbush restated an “outperform” rating and set a $87.00 target price on shares of Pacira Pharmaceuticals in a research report on Wednesday, August 23rd. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $53.00.

Pacira Pharmaceuticals (NASDAQ PCRX) traded down 0.94% during trading on Thursday, reaching $36.80. The company had a trading volume of 171,448 shares. The firm’s 50 day moving average price is $38.74 and its 200 day moving average price is $44.82. Pacira Pharmaceuticals has a 12-month low of $29.95 and a 12-month high of $58.95. The firm’s market capitalization is $1.48 billion.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.05) by $0.06. The company had revenue of $70.90 million during the quarter, compared to analyst estimates of $73.37 million. Pacira Pharmaceuticals had a negative net margin of 23.36% and a negative return on equity of 12.44%. The company’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.21 EPS. Analysts anticipate that Pacira Pharmaceuticals will post ($0.17) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Pacira Pharmaceuticals, Inc. (PCRX) Earns Market Perform Rating from Analysts at CIBC” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/07/pacira-pharmaceuticals-inc-pcrx-earns-market-perform-rating-from-analysts-at-cibc.html.

In other Pacira Pharmaceuticals news, CEO David M. Stack sold 28,885 shares of the stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $36.37, for a total value of $1,050,547.45. Following the transaction, the chief executive officer now owns 159,164 shares in the company, valued at $5,788,794.68. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CAO Kristen Marie Williams sold 3,461 shares of the stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $36.75, for a total value of $127,191.75. Following the completion of the transaction, the chief accounting officer now owns 21,312 shares in the company, valued at approximately $783,216. The disclosure for this sale can be found here. In the last quarter, insiders sold 33,390 shares of company stock worth $1,215,480. Corporate insiders own 6.60% of the company’s stock.

A number of large investors have recently made changes to their positions in the business. Fisher Asset Management LLC lifted its holdings in shares of Pacira Pharmaceuticals by 1.4% in the third quarter. Fisher Asset Management LLC now owns 6,282 shares of the company’s stock valued at $215,000 after purchasing an additional 85 shares in the last quarter. Legacy Capital Partners Inc. lifted its holdings in shares of Pacira Pharmaceuticals by 0.4% in the second quarter. Legacy Capital Partners Inc. now owns 23,200 shares of the company’s stock valued at $783,000 after purchasing an additional 100 shares in the last quarter. Fox Run Management L.L.C. lifted its holdings in shares of Pacira Pharmaceuticals by 0.8% in the third quarter. Fox Run Management L.L.C. now owns 13,400 shares of the company’s stock valued at $459,000 after purchasing an additional 100 shares in the last quarter. Mutual of America Capital Management LLC lifted its holdings in shares of Pacira Pharmaceuticals by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 24,198 shares of the company’s stock valued at $1,858,000 after purchasing an additional 142 shares in the last quarter. Finally, Rothschild Asset Management Inc. lifted its holdings in shares of Pacira Pharmaceuticals by 2.5% in the third quarter. Rothschild Asset Management Inc. now owns 7,137 shares of the company’s stock valued at $244,000 after purchasing an additional 175 shares in the last quarter.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.